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Insulin analogues have been engineered to enhance desired molecular properties without altering immunogenicity. The majority of insulin
pharmacology studies are conducted in healthy volunteers and patients with type 1 diabetes. At present, there are more patients with type
2 than type 1 diabetes receiving insulin treatment. As the responsibility for initiating insulin therapy in these patients continues to shift to
primary care, it will be important for general practitioners to understand the different pharmacological properties of insulin preparations in
patients with type 2 diabetes, so that treatment can be adapted to meet patients’ physiological and lifestyle requirements. The purpose of this
review is to summarize pharmacological studies of insulin analogues in patients with type 2 diabetes. Faster onset of action of rapid acting
insulin analogues has improved postprandial glycaemic control. Biphasic insulin analogues are associated with a lower incidence of nocturnal
hypoglycaemia compared with human biphasic preparations and allow for intensiﬁcation from once to twice or thrice daily dosing. More
predictable glycaemic-lowering proﬁles of the insulin analogues have also led to reductions in nocturnal hypoglycaemia, particularly comparing
long-acting insulin analogues with protaminated human insulin. Enhancing insulin self-association and reversible binding with albumin has
led to further reductions in variability. However, improvements can still be made. Effective once daily clinical dosing of long-acting insulin
analogues is not possible in all patients. In addition, the protaminated component of biphasic insulin analogues do not provide the duration of
action or proﬁle for physiological basal insulin replacement and neither insulin glargine nor insulin detemir are suitable for mixing with other
insulin analogues as this would substantially alter their pharmacokinetic properties. Enhancing the pharmacological predictability and extending
the duration of action could simplify insulin titration and further reduce the incidence of hypoglycaemia.
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Introduction
Insulin, a 51 amino acid 5.7 kDa protein comprised of an A
and B chain linked by two di-sulphide bridges and produced
by pancreatic islet β cells, is one of the best-known and
most-studied proteins. First isolated in 1921 and used as a
treatment of type 1 diabetes in 1922, insulin has advanced
from early animal to biosynthetic human and analogue
preparations and is increasingly used to treat type 2 diabetes
at various stages of disease progression. The advance from
animal to human preparations had obvious advantages linked
tosequencehomologywiththenativehumanprotein,reducing
the incidence of antibody formation that led to injection site
reactions and blocking of therapeutic effect. More recently,
insulin analogues have been engineered to enhance desired
molecular properties (e.g. rapid absorption or prolonged
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duration of action) without altering immunogenicity. These
improvements have enabled physicians to tailor treatment
regimens and more closely emulate the normal insulin
physiology comprised of a stable basal secretion with surges of
insulin closely temporally related to food ingestion (reaching
maximal concentrations 45–60 min and returning to baseline
within 2–3 h) [1].
Studies of pharmacokinetics and pharmacodynamics are an
integral part of clinical drug development and are particularly
important to insulin clinical development where the aim has
been to mimic the normal physiology of insulin secretion and
action in relation to and between meals. Most of these studies
are conducted in healthy volunteers (low doses) to ascertain
safety and patients with type 1 diabetes (treatment doses) to
describe more fully, insulin metabolism and glucose lower-
ing effect. As patients with type 1 diabetes have no/negligible
endogenous insulin, the measurements of insulin, glucose and
other metabolic effects are ascribed to the administration of
exogenous insulin.
The site of injection [2], thickness of the subcutaneous
tissue [3,4], subcutaneous blood ﬂow [5–7] and the amountreview article DIABETES, OBESITY AND METABOLISM
of insulin administered [8] have all been reported to inﬂuence
human insulin pharmacokinetics. In addition, human insulin
pharmacokinetics has been shown to be different in patients
with type 2 compared with type 1 diabetes and may also
be altered by the presence of obesity. Clauson and Linde [9]
reported 15–45% slower absorption kinetics of human insulin
(Actrapid) in obese and normal body weight type 2 diabetes
patients relative to previously studied patients with type 1
diabetes.Justasinpatientswithtype1diabetes,thehighestrates
ofabsorptionwereseenfollowingsubcutaneousadministration
to the epigastric area in normal body weight patients with type
2diabetes,however,nodifferencesinabsorptionratesbetween
various injection sites were seen in the obese patients with type
2 diabetes. Ryysy et al. [10] found that increases in total body
adiposityratherthansubcutaneousthicknessweremostclosely
associated with insulin dose and delayed insulin absorption.
With the number of patients with type 2 diabetes receiving
insulin treatment presently exceeding the number of patients
with type 1 diabetes and the responsibility for initiating
insulin therapy in these patients continuing to shift to
primary care [11], it will be increasingly important for general
practitioners to understand the pharmacological properties of
currently available and emerging insulin preparations in type
2 diabetes patients, so that treatment can be adapted to meet
patients’ physiological and lifestyle requirements.
Thisreviewsummarizespharmacokineticandpharmacody-
namic studies of insulin analogues performed in patients with
type 2 diabetes.
Methodology
Relevant publications were identiﬁed by means of a PubMed
literature search using the following criteria: (‘insulin’)
AND (‘lispro’ OR ‘aspart’ OR ‘glulisine’ OR ‘glargine’ OR
‘detemir’)AND(‘type2diabetes’)AND(‘pharmacokinetic’OR
‘pharmacodynamic’). Other studies were identiﬁed from the
bibliography of short-listed articles. The search was limited to
English language publications. An initial review of all titles and
abstracts was performed for relevance. If deemed appropriate
for further review, access to the full article was obtained. The
ﬁguresincludedinthisreviewrelatingtoinsulinconcentration,
glucose infusion rate (GIR) and blood glucose proﬁles were
reconstructedfrompreviouslypublishedﬁguresusingthesemi-
automated software, Digitize It v1.5 (Eden Prairie, Minnesota,
USA) [12].
Insulin Analogues
Under normal physiological circumstances, insulin is synthe-
sized in the pancreatic β cells and stored in vesicles of the
Golgi-apparatus in relatively high quantity. In the vesicles of
the β cell insulin is stored as hexamers, which form as a result
ofthehighlocalinsulinconcentrationandthepresenceofzinc.
When released to the circulation, these insulin hexamers dis-
sociate to form dimers and monomers, because of the dilution
effect and zinc diffusing away. Insulin molecules in solution
exist in dynamic equilibrium as monomers, dimers, double
dimers (tetramers), triple dimers (hexamers) and higher-order
aggregates. The extent of insulin self-association is dependent
on factors that include insulin concentration, zinc concentra-
tionandpH.Alteringthesolventcompositionandtheprimary
structure of insulin can also affect the charge and solubility of
the insulin molecule.
Beforetheadventofinsulinanalogues,theprincipalmethod
of delaying absorption of injectable insulin preparations
was through adding protamine and/or zinc to stabilize
insulin hexamers [13]. The breakdown of protamine and/or
dissipation of zinc following subcutaneous injection de-
stabilizes the hexamers and results in the slow release of
dimers and monomers. The addition of protamine and zinc
is not a process limited to animal and human insulin, but is
also seen in production of some insulin analogue preparations.
Biphasic insulin analogues, for example, comprise a mixture
of soluble and protaminated or precipitated insulin lispro or
insulin aspart in a range of speciﬁc ratios.
As insulin monomers and dimers enter the capillary system
at a faster rate than hexamers and only monomeric or dimeric
insulinisbiologicallyactiveattheinsulinreceptor,thespeedof
hexamerdissociationdetermines,toalargeextent,theobserved
pharmacokinetic(circulatinginsulinconcentration)andphar-
macodynamics (glucose lowering) proﬁles of an insulin
preparation [14,15]. Soluble human insulin also consists of
hexamers, which dissociate into dimers and monomers at the
injectionsite.Thelagphasebetweeninjectionofhexamersand
the availability of biologically active dimers and monomers at
target tissues, necessitates that soluble human insulin be given
30 min or so before meal consumption [16]. In addition, iden-
tical doses of insulin do not result in identical pharmacological
response either between subjects or within the same individual
at different times. This between- and within-subject variability
in pharmacological action, which in turn results in unpre-
dictableeffectswithhypoglycaemiaandhyperglycaemia,ispar-
ticularly problematic with human insulin preparations. These
limitations have fuelled the development of insulin analogues.
Broadlyspeakingtherearecurrentlytwodifferentcategories
of insulin analogues: rapid acting insulin analogues (insulin
lispro, insulin aspart and insulin glulisine); and long-acting
insulin analogues (insulin glargine and insulin detemir).
Biphasic insulin analogues are a mixture of soluble and
protaminated or precipitated forms of either insulin lispro
orinsulinaspart.Changestotheinsulinmoleculehavefocused
ontheBchain,awayfromreceptorbindingelements.Withthe
exception of insulin detemir, the other insulin analogues have
been developed through the substitution or addition of amino
acids that result in changes to the charge and/or conformation
of the insulin molecule at physiological pH (ﬁgure 1). Insulin
lispro is formed by switching lysine and proline amino acids at
positionsB28andB29andinsulinaspartbysubstitutingproline
with a negatively charged aspartic acid in position B28. Insulin
glulisine differs from human insulin by substituting aspargine
forlysineatpositionB3andlysineforglutamicacidatposition
B29 and unlike the other two rapid-acting analogues, does
not contain zinc. Rapid-acting insulin analogue modiﬁcations
weaken the propensity for the insulin to self-associate through
charge repulsion at the sites where insulin monomers would
normallyassociatetoformdimers,resultinginrapidabsorption
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Figure 1. Summary of the changes made to the insulin molecule using
singlelettercodingforamino-acids.A,alanine;C,cysteine;D,asparticacid;
E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K,
lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine;
R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine.
of monomers from the subcutaneous tissue at the time
of injection [17]. Insulin glargine is formed by replacing
asparagine with glycine at position A21 and lengthening the B
chain by adding two arginine amino acids at the C terminus.
These modiﬁcations shift the isoelectric point (the pH at
which the molecule carries no electrical charge) towards a
more neutral pH, making it less soluble at physiological pH
andpromotingprecipitationfollowingsubcutaneousinjection.
Subsequentenzymaticremovalofthetwoarginineaminoacids
at the B chain terminus occurs at a variable rate, both at the
site of injection and in the circulation, yielding products which
remain metabolically active at the insulin receptor [18].
Insulin detemir is unique in the sense that a C14 fatty acid
has been covalently bonded to lysine in position B29 and the
terminal threonine of human insulin in position B30 has been
removed. This fatty acid side chain not only increases self-
association into hexamers and di-hexamers, but also allows
reversible binding of insulin detemir to albumin present in all
tissue and in the circulation. Albumin binding contributes
almost as much to the prolongation of action of insulin
detemir, as does the di-hexameric self-association [19]. This
approach to prolonging duration of action also confers several
other advantages such as a buffering of insulin concentration
resulting in improved predictability, as well as hypothesized
hepato-selectivity which might explain the weight sparing
effects reported with this insulin [20].
Mitogenicity
There is continuing debate concerning the risk of cancer and
theassociationwithinsulinuseinpatientswithtype2diabetes.
Both the presence of obesity and diabetes are documented,
risk factors for the development of cancer per se. Insulin may
also potentially increase the risk of cancer through growth
promoting and anabolic effects mediated by binding to the
type 1 insulin-like growth factor (IGF) receptor [21]. The
type 1 IGF receptor binding has been linked to tumour
development in rodents [22] and these ﬁndings have led to
the discontinuation of speciﬁc insulin analogues. Currently
available insulin analogues exhibit an afﬁnity for the type 1
IGF receptor ranging between 16 and 641% relative to native
humaninsulin, depending on the speciﬁc insulin analogueand
cell line studied [23,24,57]. The speed of insulin dissociation
from the insulin receptor may also contribute to the mitogenic
potential of insulin analogues[23].
A series of recently published epidemiological studies have
attempted to investigate the effects of insulin use on cancer
risk [25–31]. These studies have reported mixed results. The
largeststudyof127 031patientsreportedanincreaseintherisk
of cancer with higher doses and longer duration of exposure
to any insulin and that after adjusting for insulin dose, insulin
glargine-treated patients were at highest risk [26]. Another
study of 114 842 patients reported an association between
insulin glargine used alone and increased risk of breast can-
cer [27].Currieet al. [31]alsoreportedanassociationbetween
the use of any insulin and cancer risk relative to patients
receiving oral antidiabetic drug treatment, with no additional
attributable risk of insulin glargine over other (predominantly
human) insulin preparations. Lastly, a smaller study of 12 842
patients followed for 4 years also found an association between
exclusive insulin glargine use and the risk of cancer, but not
overalluseofinsulinglargine [28].Theseepidemiologicalstud-
ies, however, are liable to a number of inherent weaknesses in
study design, the main limitation being the inability to control
for confounding factors which importantly included weight,
duration of diabetes and smoking in some instances. No evi-
dence for increased cancer risk has been reported during an
extended trial investigating the effects of neutral protamine
Hagedorn (NPH) insulin and insulin glargine effects on the
development of retinopathy [29] or in the meta-analysis of
31 insulin glargine studies [30]. Similarly, a meta-analysis of
trials comparing insulin detemir and insulin glargine reported
comparable risk of malignancy between each other and to
NPH [25]. However, as these post hoc analyses are based on
limited duration trials that were not speciﬁcally designed to
investigate mitogenic potential, these ﬁndings should also be
interpreted with caution.
The recently published consensus guidelines issued by the
American Diabetes Association and American Cancer Society
conclude that the evidence for speciﬁc diabetes drugs affecting
the risk of cancer is limited and that overriding diabetes
indicationsratherthanputativecancerconcernsshouldremain
the principal consideration when selecting therapy in patients
with type 2 diabetes [32].
Pharmacokinetics
Several pharmacokinetic parameters describe the absorption,
distribution, metabolism and elimination of a drug. Insulin
absorption is derived principally through the measure
of circulating insulin concentration in relation to time
since subcutaneous injection. The evaluation of insulin
pharmacokinetics has traditionally been undertaken by the
measurements of plasma immunoreactive insulin levels after
administration of the preparation in question. Such studies
Volume 13 No. 8 August 2011 doi:10.1111/j.1463-1326.2011.01395.x 679review article DIABETES, OBESITY AND METABOLISM
are conducted in normal subjects and patients with type
1 diabetes. Pharmacokinetic action proﬁles have also been
evaluated using the euglycaemic clamp technique in normal
subjects and patients with type 1 and 2 diabetes, whereby GIRs
are examined during maintenance of plasma glucose levels
at a predetermined value. These systemic measurements have
also been strengthened by measurements of disappearance
of radioactivity after subcutaneous administration of various
radiolabelled insulin preparations. Together, the measures
provide a complete description of the way in which the body
processes the insulin from administration to elimination.
Ideally, insulin concentrations should show dose propor-
tionality (i.e. for an increase or decrease in the administered
dose, there is a proportional increase or decrease in the insulin
concentration) and the proﬁle of insulin concentration over
timeshouldresemblethedesiredglucoseloweringproﬁle.Thus
for rapid-acting insulin analogues, the insulin concentration
should rise to a peak very quickly after injection and be rapidly
metabolized to inactive metabolites and eliminated. Duration
of action of currently available rapid acting insulin can vary
between 3 and 5 h depending on the dose injected [33]. For
long-actinginsulinanalogues,theinsulinconcentrationshould
be consistent and stable. It should be noted, however, that the
waninginsulinconcentrationofcurrentbasalinsulinanalogues
may not provide for the increase in morning insulin needed to
cover the transient morning increase in insulin resistance (i.e.
the dawn phenomenon) [34]. For biphasic insulin analogues,
the ideal proﬁle would be a combination of both a rapid onset
and peak insulin action following injection to cover the post-
prandialperiod,followedbyarapidreturntoalongﬂatproﬁle
to cover basal needs. Current biphasic formulations are not
ideal in this respect.
Figure 2 shows the pharmacokinetic proﬁles of rapid-
acting, biphasic and long-acting insulin analogues exclusively
evaluated in patients with type 2 diabetes [35–37]. The
proﬁles of human soluble and biphasic human insulin
have been included for reference [37,38]. The rapid acting
insulin analogue proﬁles mimic the normal physiological
insulin secretion in response to meals better than regular
human insulin, with a faster onset and higher maximal
concentration [37]. The long-acting insulin analogue proﬁles,
however,despitebeinganimprovementinrelationtoNPH,are
notentirelyﬂatanddonotremainconsistentovera24-hperiod.
Both biphasic insulin analogues show more rapid absorption
relative to biphasic human insulin and clearly distinguishable
peak concentrations proportional to the dose of the soluble
rapid-acting component [38]. However, the return to basal
insulin levels is slow and uneven. This part of the biphasic
insulinproﬁleis commonlyreferredtoasthe‘shoulder’,which
occurs as a result of the interaction between soluble and
protaminated insulin molecules [37,39].
One of the other interesting observations is that the
absolute quantities of insulin measured vary, most notably
between insulin detemir and the other insulin analogues. The
higherinsulinconcentrationsseenwithinsulindetemirreﬂects
both the free and albumin bound (99% in plasma) insulin
concentration, however, only the free insulin is available to
interact with the target insulin receptor.
Pharmacodynamics
In many ways, the shape of the desired pharmacodynamic
insulin proﬁle is similar to the pharmacokinetic proﬁle, that is
rapid onset and offset for the rapid-acting insulin analogues,
and a long, ﬂat and steady proﬁle for long-acting insulin
analogues.
One of the most commonly performed pharmacodynamic
studies of insulin is the clamp study [40]. In a clamp study,
subjects’bloodglucoselevelsarekeptwithinaspeciﬁcrangeor
underacertainthresholdmeasurementbyinfusingintravenous
glucose. The amount of glucose infused to maintain blood
glucose levels represents the amount of glucose uptake into the
cells induced by insulin receptor activation. This is referred to
as the GIR. Results of pharmacodynamic studies of patients
with type 1 diabetes are easier to interpret as almost all glucose
lowering is attributed to the study insulin. As already eluded
to, clamp studies may employ different glycaemic thresholds
and use different glucose-monitoringtechniques.To minimize
potential human error, the Biostator automates the process of
monitoring and infusing glucose. This is important as over-
infusion of glucose would result in a peak in the measured
proﬁle and also consume more insulin potentially resulting
in an apparently shorter duration of action and vice versa.
As with the array of differing deﬁnitions of hypoglycaemia,
the lack of consensus on the way in which pharmacodynamic
clamp studies are performed is a source of confusion. Through
variationinglucosemonitoringtechniques,thechoiceofclamp
glucosethresholds,thedeﬁnitionofendofaction,thetimingof
injections in relation to the start of the clamp and the differing
protocols with respect to the use of insulin infusion to switch
off hepatic gluconeogenesis, published clamp studies are very
difﬁcult to compare relative to each other.
Figure 3 presents GIR proﬁles of the insulin analogues
obtained in patients with type 2 diabetes [35,36,41]. In
patients with type 2 diabetes, both insulin lispro and insulin
aspart administered immediately before meals have showed
an 18–48% reduction in the rise of the 2-h postprandial
glucose relative to human insulin given 30 min before the
meal [37,42,43]. Insulin lispro and insulin glulisine have been
shown to be equivalent on all glucose infusion measures
in patients with type 2 diabetes, with the exception of a
0.5 mmol/l lower glucose excursion with insulin glulisine in
type 2 patients with obesity [44]. There are no other studies
comparing rapid-acting insulin analogues in patients with type
2diabetes,orcomparisonsofthepharmacologyofrapid-acting
insulin analogues in type 2 relative to type 1 diabetes.
The pharmacodynamics of insulin lispro mix 25 has been
derived from cross-over trials in patients given a standard test
meal [45,46], which resulted in a lower peak rise in serum
glucose compared with biphasic human insulin and NPH. In
a similar experiment, biphasic insulin aspart 30 was found to
have 44 and 34% lower postprandial glucose concentrations
compared with biphasic human insulin 30 after breakfast and
dinner,respectively [47].Theseﬁndingsareconsistentwiththe
differencesbetweenrapidinsulinanaloguesandhumaninsulin.
Furthermore, for those patients requiring a higher proportion
of rapid-acting insulin, there is good evidence showing the
relative increases in early postprandial glucose utilization with
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(a)
(b)
Figure 2. Insulin concentration from published pharmacokinetic studies conducted in patients with type 2 diabetes (a) insulin aspart (0.15 U/kg) [37],
human soluble insulin (0.15 U/kg) [37], biphasic insulin aspart 30/70 (0.6 U/kg) [36], and biphasic human insulin 30 (0.6 U/kg) [36] and (b) insulin
detemir (0.8 U/kg) [35].
the higher ratio biphasic preparations (e.g. biphasic insulin
aspart 50/50 and 70/30 [48–50], and biphasic insulin lispro
50/50 and 75/25). In addition, Parkner et al. [51] speciﬁcally
compared normal and obese patients with type 2 diabetes with
respecttoinsulinpharmacodynamicsofbiphasicinsulinaspart
andfoundnorelationshipbetweenbodymassindexandblood
glucose excursions. A single published clamp experiment [39]
showed that for equivalent unit doses, the overall glucose
lowering effect was greater for biphasic insulin aspart twice
dailycomparedwithinsulinglargineoncedaily.Theseﬁndings,
however, are counterintuitive as an equivalent dose implies
equivalent biological effect. Furthermore, a higher peak effect
of the evening biphasic insulin aspart dose in this study led to
recommendations by the authors to split doses 2/3 am and 1/3
pm to avoid increasing the risk of nocturnal hypoglycaemia.
Asthefunctionoflong-actinginsulinanaloguesistoprovide
basal coverage, ideally the GIR proﬁles should not only have
no signiﬁcant peak effect, but also show minimal day-to-day
intra-patient variability. Whilst differences between patients
are acceptable, variable responses to the same insulin dose
within the same patient can increase the risk of hypoglycaemia
and hyperglycaemia. Improved intra-patient variability has
been shown with insulin detemir. In the study by Klein
et al. [20] within-patient variability was signiﬁcantly lower
with insulin detemir than with insulin glargine in patients
with type 2 diabetes, both in terms of the overall 24-h
glucoseloweringeffect(47 vs.215%variation)andthemaximal
glucose lowering effect (40 vs. 147% variation). Furthermore,
althoughthedurationofactionincreaseswithescalatinginsulin
doses [20], currently available long-acting insulin analogues
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Figure 3. Glucose lowering effect from published pharmacodynamics studies conducted in patients with type 2 diabetes as measured by the glucose
infusionrate(GIR)forinsulinaspart(0.3U/kg) [41],humansolubleinsulin(0.3U/kg) [41],biphasicinsulinaspart30/70(0.6U/kg) [36],biphasichuman
insulin 30 (0.6 U/kg) [36], insulin detemir (0.8 U/kg) [35] and insulin glargine (0.8 U/kg) [35]. All insulin preparations were administered at time = 0h .
probably do not last 24 h, particularly at low doses. In single
dose experiments, even doses of 0.8 U/kg achieved less than
24 h basal coverage in a signiﬁcant proportion (up to 74%)
of fasting patients with type 2 diabetes [35] and that almost
twicethisamountofinsulinisrequiredtoachieve24-hcoverage
underexperimentalconditions [20].Lastly,severalstudieshave
reportedclearpeakeffects8–12 hafteradministrationforboth
insulin glargine and insulin detemir in this patient population
after a single dose administration [20,35,39].
Insulin preparations are most commonly studied in single
dose, that is, a single dose is administered and the effects
are measured. Single dose studies are more clinically relevant
for assessing the pharmacology of rapid-acting insulin and
are also useful in measuring onset of action. However, as
peak effects may be exaggerated in single dose studies of
long-acting insulin analogues and the concept of long-acting
insulin is to provide continuous basal coverage, steady-state
pharmacodynamicstudiesareprobablymoreclinicallyrelevant
in this situation. Steady state is said to occur when there is an
identical metabolic effect with subsequent doses. Essentially,
the drug concentration is in equilibrium, where the amount
metabolized to inactive metabolites and/or eliminated is the
same as the amount of drug administered. Steady state can
be achieved with all drugs and is dependent on the frequency
of administration and the drug half-life. For drugs that follow
ﬁrst order kinetics (i.e. a constant fraction of the drug in the
body is eliminated for each unit of time, which applies to the
majority of drugs) drug concentrations reach to within 98% of
thesteady-stateconcentrationatapproximatelythreetimesthe
drug half-life. Unfortunately, to the authors’ knowledge, there
are no published studies of steady-state insulin pharmacology
in patients with type 2 diabetes.
Ingeneral,themagnitudeofthepeakintheglucoselowering
effect of long-acting insulin is inversely proportional to the
duration of action. For example, for the same dose, the peak
effect of NPH is higher than those for the longer duration
insulin glargine and insulin detemir. By slowing absorption
further conditions for steady state are improved and thus the
proﬁle can be made ﬂatter and more consistent with the basal
insulin replacement/supplementation concept.
Conclusions
Human insulin preparations including soluble, protami-
nated/precipitatedandbiphasicvariantsareappreciatedtohave
limitationsintermsofvariabilityofabsorptionandthusglucose
loweringaction.Insulinanaloguesprovideclinicianstheoppor-
tunity to more closely emulate normal insulin physiology and
toselectdifferentinsulinregimensdependingonpatientprefer-
encesandlifestyle,thusmakinginsulintreatmentlessrestrictive
todifferentcircumstances.Fasteronsetofactionofrapidacting
insulinanalogueshasimprovedpostprandialglycaemiccontrol
in patients with type 2 diabetes [37,38,47,52–54]; and more
predictableglycaemicloweringproﬁlesoftheinsulinanalogues
have also led to reductions in reported nocturnal hypogly-
caemia, particularly comparing long-acting insulin analogues
with NPH. A move away from suspensions of crystals contain-
ing protamine–insulin complexes and in vivo precipitation as
the principal method of prolonging insulin absorption, has led
to further reductions in within-patient variability [55,56].
Improvementscanstillbemade,however,particularlyinthe
areaoflong-actinginsulinanalogues,whereeffectiveoncedaily
clinicalusemightnotbepossibleinallpatientsandmayrequire
patients to administer insulin at a speciﬁc time of day which
may not always be convenient or remembered. In addition,
whilstclinicianshavecometoexpectbetweensubjectvariations
because of different insulin requirements and hence the need
for individual titration based on frequent blood glucose
monitoring, a more consistent proﬁle between individuals
would be expected to simplify management. Even with the
insulin analogues, successful treatment with any regimen still
requires careful individual titration according to frequently
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measured blood glucose. This in itself is a problem as titration
is a time consuming, continuous and often frustrating process;
and patients are often punished in terms of deterioration in
glycaemic control following even minor errors in dosing.
Finally, whilst biphasic insulin analogues have been shown
to be associated with a lower incidence of nocturnal
hypoglycaemia compared with human mix insulin and allow
for intensiﬁcation from once, to twice or thrice daily dosing,
the protaminated/precipitated component does not provide
the duration of action or proﬁle for physiological basal insulin
replacement. In essence, biphasic insulin is a mixture of
rapid and intermediate acting insulin, that is, carrying the
same limitationsas theindividual components. Unfortunately,
neither insulin glargine nor insulin detemir are suitable for
mixingwithotherinsulinanaloguesasthismixingsubstantially
alters their pharmacokinetic properties.
Furtherimprovementsinreducingthepharmacologicalvari-
ability of rapid- and long-acting insulin would be expected to
lower the risk of hypoglycaemia and hyperglycaemia, as well as
simplify and perhaps also encourage, optimal insulin titration
in real-life clinical practice. Extending the duration of insulin
effect would also allowfor greaterﬂexibilityaround the timeof
dosing and potentially reduce the frequency of blood glucose
monitoring.
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